• Bate, R., Jin, GZ., Marthur, A. 2015. Falsified od substandard? Assessing price and non-price signals of drug quality. Journal of Economics & Management Strategy. DOI: 10.1111/jems.12114. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/jems.12114
  • Clark, CL. 2019. Substandard and falsified medical products a global issue affecting the health of woman and children. The American Journal of Maternal/Child Nursing. DOI: 10.1097/NMC.00000579. Available from: https://journal.lww.com/mncjournal
  • Ciapponi, A., Donato, M., Gulmezoglu, AM., Alconada, T., Bardach, A. 2021. Mobile apps for detecting falsified and substandard drugs: a systematic review. PLoS One. DOI: 10.1371/journal.pone.0246061. Available from: https://pubmed.ncbi.nlm.nih.gov/33539433/
  • El-Dahiyat, F., Fahelelbom, K., Jairoun, AA., Al-Hemyari, SS. 2021. Combatting substandard and falsified medicines: public awareness and identification of counterfeit medication. Front Public Health. DOI: 10.3389/fpubh.2021.754279. Available from: https://pubmed.ncbi.nlm.nih.gov/34765583/
  • Fantasia, HC., Vooys, KM. 2018. Public health implications of counterfeit medicines. Nurs Womes Health. DOI: 10.1016/j.nwh.2018.03.001. Available from: https://pubmed.ncbi.nlm.nih.gov/29885715/
  • Ferrario, A., Orubu, ES., Adeyeye, MC., Zaman, MH., Wirtz, VJ. 2019. The need for comprehensive and multidisciplinary training in substandard and falsified medicines for pharmacists. BMJ Global Health. DOI: 10.1136/bmjgh-2019-001681. Available from: https://gh.bmj.com/content/bmjgh/4/4/e001681.full.pdf
  • Friedrich, MJ. 2018. Dangers of substandard or falsified medicines. JAMA. DOI: 10.1001/jama.2017.21921. Available from: https://pubmed.ncbi.nlm.nih.gov/29340691/
  • Ghanem, N. 2019. Substandard and falsified medicines: global and local efforts to address a growing problem. The Official Journal of Royal Pharmaceutical Society. Available from: https://pharmaceutical-journal.com/article/research/substandard-and-falsified-medicines-global-and-local-efforts-to-address-a-growing-problem
  • Hart, IM., Ohana, D., Venhuis, BJ. 2021. Current challenges in the detection and analysis of falsified medicines. Journal of Pharmaceutical and Biomedical Analysis. DOI: 10.1016/j.pba.2021.113948. Available from: https://www.sciencedirect.com/science/article/pii/S0731708521000601
  • Hauk, C., Hagen, N., Heide, L. 2021. Identification of substandard and falsified medicines: influence of different tolerance limits and use of authencitiy inquiries. The American Journal of Tropical Medical and Hygine. DOI: 10.4269/ajtmh.20-1612. Available from: https://pubmed.ncbi.nlm.nih.gov/33788775/
  • Hoen, E. and Pascual F. 2015. Viewpoint: Counterfeit medicines and substandard medicines: different problems requiring different solutions. Journal of Public Health Policy. DOI: 10.1057/jphp.2015/22. Available from: https://link.springer.com/article/10.1057/jphp.2015.22#citeas
  • Khurelbat, D., Dorj, G., Sunderland, B., Sanjjav, T., Bayarsaikhan, E., Damdinjav, D., Jigjidsuren, A., Lkhagvsuren, O., Erdenetsetseg, B. 2020. A cross-sectional analysis of falsified, counterfeit and substandard medicines in a low-middle income country. BMC Public Health. DOI: 10.1186/s12889-020-08897-x. Available from: https://link.springer.com/content/pdf/10.1186/s12889-020-08897-x.pdf
  • Lee, KS., Yee, SM., Zaidi, ST., Patel, RP., Yang, Q., Worafi, YM., Ming, LC. 2017. Combating sale of counterfeit and falsified medicines online: a losing battle. Frontiers in Pharmacology. DOI: 10.3389/fphar.2017.00268. Available from: https://www.frontiersin.org/articles/10.3389/fphar.2017.00268/full
  • Mackay, TK. 2018. Prevalence of substandard and falsified essential medicines still an incomplete picture. JAMA Network Open. DOI: 10.1001/jamanetworkopen.2018.1685. Available from: https://jamanetwork.com/journals/jamanetworkopen/article-abstract/2696502
  • McManus, D., Naughton, BD. 2020. A systematic review of substandard, falsified, unlicensed and unregistered medicine sampling studies: a focus on context, prevalence, and quality. BMJ Global Health. DOI: 10.1136/bmjgh-2020-002393. Available from: https://gh.bmj.com/content/bmjgh/5/8/e002393.full.pdf
  • Nayyar, G., Breman JG., Herrington, JE. 2015. The global pandemic of falsifies medicines: laboratory and field innovations and policy perspectives. The American of Tropical Medicines and Hygiene. DOI: 10.4269/ajtmh.15-0221. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4455081/pdf/tropmed-92-2.pdf
  • Nayyar, G., Breman, JG., Mackey, T., Clark, J., Hajjou, M., Littrell, M., and Herrington, J. 2019. Falsified and substandard drugs: stopping the pandemic. The American Journal of Tropical Medical  and Hygiene. DOI: 10.4269/ajtmh.18-0981. Available from: https://pubmed.ncbi.nlm.nih.gov/30860016/
  • Olliaro, E., Olliaro, P., Ho, CW., Ravinetto, Raffaella. 2020. Legal uncertainty-the gray area around substandard medicines: where public health meets law. The American Journal of Tropical Medical and Hygiene. DOI: 10.4269/ajtmh.19-0645. Available from: https://pubmed.ncbi.nlm.nih.gov/31746313/
  • Ozawa, S., Evans, DR., Bessias, S., Haynie, DG., Yemeke, TT., Laing, SK., Herrington, JE. 2018. Prevalence and estimated economic burden of substandard and falsified medicines in low-and middle-income countries: a systematic review and meta-analysis. JAMA. DOI: 10.1001/jamanetowrkopen.2018.1662. Available from: https://pubmed.ncbi.nlm.nih.gov/30646106/
  • Pisani, E., Nistor, AL., Hasnida, A., Parmaksiz, K., Xu, J., and Kok, M. 2018. The political economy of substandrd and falsified medicines: an evidence-informed risk-assessment framework based on multi-countri study. DOI: 10.13140/RG.2.2.30137.62563. Available from: Researchget
  • Pisani, E., Nistor, AL., Hasnida, A., Parmaksiz, K., Xu, J., and Kok, M. 2019. Identifying market risk for substandard and falsified medicines: an analytic framework based on qualitative research in China, Indonesia, Turkey and Romania. Wellcome Open Research. DOI: 10.12688/wellcomeopenres.15236.1. Available from: https://pubmed.ncbi.nlm.nih.gov/31131333/
  • Pisani, E., Hasnida, A., Mawadatti, R., Kok, M.O., Harsono, S., and Anggriani, Y. 2021. Substandard and falsified medicines: proposed methods for case finding and sentinel surveillance. JMIR Public Health Surveill. DOI:10.2196/29309. Available from: https://pubmed.ncbi.nlm.nih.gov/34181563
  • Rahman, MS., Yoshida, N., Tsuboi, H., Tomizu, N., Endo, J., Miyu, O., Akimoto, Y., Kimura, K. 2018. The health consequences of falsified medicines- A study of the published literature. Tropical Medicine & International Health. DOI: 10.1111/tmi.13161. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/tmi.13161
  • Rasheed, H., Hollein, L., Holzgrabe, U. 2018. Future information technology tools for fighting substandard and falsified medicine in low-and middle-income countries. Frontiers in Pharmacology. DOI: 10.3389/fphar.2018.00995. Available from: https://pubmed.ncbi.nlm.nih.gov/30233373/
  • Sammons, HM. and Choonara, I. 2018. Substandard medicines: a greater problem than counterfeit medicines? BMJ Pediatrics Open. DOI: 10.1136/bmjpo-2017-000007. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5842987/
  • Shiferie, F., Kassa, E. 2020. The scourge of substandard and falsified medical products gets worse with COVID-19. The Pan African Medical Journal. DOI: 10.11604/pamj.2020.37.344.26332/ Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934180/
  • Vardanyan, L., Kazaaryan, I., Sevikyan, A., Amirkhanyan. 2021. Falsified medicines and shortage as urgent challenges in health care. European Journal of Public Health. DOI: 10.1093/eurpub/ckab164.592. Available from: https://academic.oup.com/eurpub/article/31/Supplement_3/ckab164.592/6405054?login=true

Share this :

PreviousPublication Related to Substandard & Falsified Medicines NextNews Related to Substandard & Falsified Medicines